Drug Profile
Research programme: pneumococcus pneumolysoid conjugate vaccine - Roche
Latest Information Update: 08 Mar 2011
Price :
$50
*
At a glance
- Originator Baxter Healthcare Corporation
- Developer Roche
- Class Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pneumococcal infections
Most Recent Events
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche
- 29 May 2007 Preclinical trials in Pneumococcal infections in USA (unspecified route)